Cipla, one of India’s leading generic pharmaceutical companies has reportedly decided to reduce its ballooning employee cost by freezing increments of 300-400 of its top managers as part of the company’s operational revamp. In the past five years, the company has been a laggard among its peers as management and operational changes dragged the company’s profits down. For the first quarter of FY17, the company’s employee cost rose by 11% to Rs 687 crore on a Y-o-Y basis, at a time when its profits had declined by 43% to Rs 365 crore.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.30 |
| Dr. Reddys Lab | 1234.00 |
| Cipla | 1231.50 |
| Zydus Lifesciences | 937.50 |
| Lupin | 2329.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: